Raquel Cuchacovich
Raquel Cuchacovich has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
L. R. Espinoza
Section of Rheumatology, Medicine Department, LSU Health Sciences Center, New Orleans, LA, USA
2 shared publicationsLuis R. Espinoza
Louisiana State University Health Sciences Center
2 shared publications- Arnold H. Zea
School of Medicine, LSU-Health Sciences Center, New Orleans, LA 70112, USA
1 shared publication Arthur Richert
Louisiana State University Health Sciences Center
1 shared publicationCarmen G. Espinoza
1 shared publication- Joseph L. Hagan
Baylor College of Medicine
1 shared publication
Latest Publications
- 24 October 2014
- Published by Springer Nature in Clinical Rheumatology
- Vol. 33 (12) , 1815-1821
Distinct genetic profile in peripheral blood mononuclear cells of psoriatic arthritis patients treated with methotrexate and TNF-inhibitors
Psoriatic arthritis (PsA) is a systemic inflammatory condition associated with psoriasis. Despite considerable heterogeneity in clinical presentation, genetic studies and animal models support the notion that PsA is a distinct disease. We aimed to characterize the PsA genotype by gene expression profile and to research the effect in gene modulation of methotrexate (MTX) and TNF-inhibitors (TNF-I) in PsA-treated patients. Nine PsA patients, according to CASPAR criteria, and three healthy controls were recruited from an outpatient rheumatology clinic. Three out of nine PsA patients were naïve to treatment, three received TNF-I, and the remaining three were on MTX-monotherapy. Blood samples were collected and analyzed by human genome U95 Array-Affymetrix (GeneChip® instrument system). Identification of statistically significant differences between differentially expressed genes was determined by Mann–Whitney and t test (p
- 24 October 2014
- Published by Springer Nature in Clinical Rheumatology
- Vol. 33 (12) , 1815-1821
Distinct genetic profile in peripheral blood mononuclear cells of psoriatic arthritis patients treated with methotrexate and TNF-inhibitors
Psoriatic arthritis (PsA) is a systemic inflammatory condition associated with psoriasis. Despite considerable heterogeneity in clinical presentation, genetic studies and animal models support the notion that PsA is a distinct disease. We aimed to characterize the PsA genotype by gene expression profile and to research the effect in gene modulation of methotrexate (MTX) and TNF-inhibitors (TNF-I) in PsA-treated patients. Nine PsA patients, according to CASPAR criteria, and three healthy controls were recruited from an outpatient rheumatology clinic. Three out of nine PsA patients were naïve to treatment, three received TNF-I, and the remaining three were on MTX-monotherapy. Blood samples were collected and analyzed by human genome U95 Array-Affymetrix (GeneChip® instrument system). Identification of statistically significant differences between differentially expressed genes was determined by Mann–Whitney and t test (p
- 1 October 2010
- Published by Springer Nature in Clinical Rheumatology
- Vol. 30 (1) , 133-137
Tumor necrosis factor-alpha (TNF-α)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature
To study the cytokine profile in a 52 year old woman with psoriasis, PsA, and HCV who developed hepatic sarcoidosis following Etanercept therapy for 7 months. 11 PsA patients on TNF blockers mean disease duration 158.4 (SD 114.5), mean treatment duration 72.1 (SD 42.14) months, 8/11 PsA were on Etanercept and 5 healthy controls were studied. TNF-α, sTNF RI/RII, IFN-α/β/γ, IL-1 α, IL-15, IL-6, VEGF, s IL-1 R, sIL-6 R, IL-12, IL-23, IL-17, Adiponectin, Leptin and EGF were assessed. All PsA and controls tested negative for Quantiferon TB Gold, hepatitis B/C, HIV, ACE level, chest x-ray, liver function test (LFTs). Serologic biomarkers of the subject in comparison to the controls indicate that sTNF RI value was significantly higher; and IL-1 alpha level has a high outlier compared to the 11 PsA patients on TNF blockers. The clinical course, histologic findings, increased levels of s TNF R I and IL-1 α in the subject as compared to the other PsA on TNF blockade and controls, suggest that most likely Etanercept induced inflammatory cytokine imbalance was responsible for inducing hepatic sarcoidosis.
- 1 October 2010
- Published by Springer Nature in Clinical Rheumatology
- Vol. 30 (1) , 133-137
Tumor necrosis factor-alpha (TNF-α)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature
To study the cytokine profile in a 52 year old woman with psoriasis, PsA, and HCV who developed hepatic sarcoidosis following Etanercept therapy for 7 months. 11 PsA patients on TNF blockers mean disease duration 158.4 (SD 114.5), mean treatment duration 72.1 (SD 42.14) months, 8/11 PsA were on Etanercept and 5 healthy controls were studied. TNF-α, sTNF RI/RII, IFN-α/β/γ, IL-1 α, IL-15, IL-6, VEGF, s IL-1 R, sIL-6 R, IL-12, IL-23, IL-17, Adiponectin, Leptin and EGF were assessed. All PsA and controls tested negative for Quantiferon TB Gold, hepatitis B/C, HIV, ACE level, chest x-ray, liver function test (LFTs). Serologic biomarkers of the subject in comparison to the controls indicate that sTNF RI value was significantly higher; and IL-1 alpha level has a high outlier compared to the 11 PsA patients on TNF blockers. The clinical course, histologic findings, increased levels of s TNF R I and IL-1 α in the subject as compared to the other PsA on TNF blockade and controls, suggest that most likely Etanercept induced inflammatory cytokine imbalance was responsible for inducing hepatic sarcoidosis.
- 1 December 2008
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 14 (6) , 353-356
Biologic Therapy(TNF-α Antagonists)-Induced Psoriasis
We report 3 patients with psoriatic arthritis and 2 with rheumatoid arthritis who developed worsening, and/or de novo psoriasis, and/or psoriasiform rash, while on tumor necrosis factor antagonist therapy. All 5 patients initially presented with active skin, and/or joint inflammatory involvement, and exhibited significant clinical response to tumor necrosis factor antagonist therapy. Within approximately 6 months, however, psoriatic and/or psoriasiform rash developed de novo in 2 rheumatoid arthritis patient and exacerbated in the other 3 patients. Biopsy findings revealed histologic and immunohistochemical changes indistinguishable from psoriasis.Psoriatic rash improved after discontinuation of biologic therapy and/or initiation of a short course of oral prednisone. One patient with psoriatic arthritis was rechallenged with infliximab due to exacerbation of both psoriasis and psoriatic arthritis, and this was followed by prompt improvement of both conditions. At 6 months follow-up, this patient remains under excellent control. To date, there have been over 50 cases of this type of dermatologic complication described. Interferon alpha seems to play an important role in the pathogenesis of this complication. This type of complication has been described with all 3 available tumor necrosis factor inhibitors, and most patients improve after discontinuation of biologic therapy.
- 1 December 2008
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 14 (6) , 353-356
Biologic Therapy(TNF-α Antagonists)-Induced Psoriasis
We report 3 patients with psoriatic arthritis and 2 with rheumatoid arthritis who developed worsening, and/or de novo psoriasis, and/or psoriasiform rash, while on tumor necrosis factor antagonist therapy. All 5 patients initially presented with active skin, and/or joint inflammatory involvement, and exhibited significant clinical response to tumor necrosis factor antagonist therapy. Within approximately 6 months, however, psoriatic and/or psoriasiform rash developed de novo in 2 rheumatoid arthritis patient and exacerbated in the other 3 patients. Biopsy findings revealed histologic and immunohistochemical changes indistinguishable from psoriasis.Psoriatic rash improved after discontinuation of biologic therapy and/or initiation of a short course of oral prednisone. One patient with psoriatic arthritis was rechallenged with infliximab due to exacerbation of both psoriasis and psoriatic arthritis, and this was followed by prompt improvement of both conditions. At 6 months follow-up, this patient remains under excellent control. To date, there have been over 50 cases of this type of dermatologic complication described. Interferon alpha seems to play an important role in the pathogenesis of this complication. This type of complication has been described with all 3 available tumor necrosis factor inhibitors, and most patients improve after discontinuation of biologic therapy.
- 31 December 2006
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 20 (4) , 735-758
Clinical Applications of the Polymerase Chain Reaction: An Update
- 31 December 2006
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 20 (4) , 735-758
Clinical Applications of the Polymerase Chain Reaction: An Update
- Open Access
- 16 September 2003
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 43 (2) , 249-250
Lower level of synovial fluid interferon- in HLA-B27-positive than in HLA-B27-negative patients with Chlamydia trachomatis reactive arthritis
Sir, We read with great interest the study by Bas et al. [1] in which they analysed synovial fluid (SF) cytokine levels in reactive arthritis (ReA), rheumatoid arthritis (RA) and osteoarthritis, and correlate them with the HLA-B27 haplotype in a subset of ReA patients positive for Chlamydia trachomatis. The results did not reveal significant differences in cytokine levels and ratios among the groups, although lower levels of interferon γ (IFN-γ) in SF were found in the HLA-B27-positive ReA patients than in the negative ones.
- 16 September 2003
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 43 (2) , 249-250
Open AccessLower level of synovial fluid interferon- in HLA-B27-positive than in HLA-B27-negative patients with Chlamydia trachomatis reactive arthritis
Sir, We read with great interest the study by Bas et al. [1] in which they analysed synovial fluid (SF) cytokine levels in reactive arthritis (ReA), rheumatoid arthritis (RA) and osteoarthritis, and correlate them with the HLA-B27 haplotype in a subset of ReA patients positive for Chlamydia trachomatis. The results did not reveal significant differences in cytokine levels and ratios among the groups, although lower levels of interferon γ (IFN-γ) in SF were found in the HLA-B27-positive ReA patients than in the negative ones.
- Open Access
- 31 March 2003
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 42 (9) , 1115-1116
Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients
Sir, We read with great interest the report by Gerli et al. [1] demonstrating in systemic lupus erythematosus (SLE) patients an association between anti‐ribosomal P antibodies and anticardiolipin antibodies [anti‐CL immunoglobulin (Ig) G isotype], as well as with a higher European concensus lupus activity measurement (ECLAM) score, photosensitivity, malar and discoid rash, and age of disease onset <33 yr old.
- 31 March 2003
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 42 (9) , 1115-1116
Open AccessClinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients
Sir, We read with great interest the report by Gerli et al. [1] demonstrating in systemic lupus erythematosus (SLE) patients an association between anti‐ribosomal P antibodies and anticardiolipin antibodies [anti‐CL immunoglobulin (Ig) G isotype], as well as with a higher European concensus lupus activity measurement (ECLAM) score, photosensitivity, malar and discoid rash, and age of disease onset <33 yr old.